Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MERTK | Q12866 | 20/20 | 1.00 |
| ▸ | AXL | P30530 | 8/20 | 1.00 |
| ▸ | TYRO3 | Q06418 | 8/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14752543 | 1.00 | MERTK (1.00) | MERTKAXLTYRO3 | |
| SCHEMBL14738968 | 1.00 | MERTK (1.00) | MERTKAXLTYRO3 | |
| SCHEMBL12185248 | 0.98 | MERTK (1.00) | MERTKAXLTYRO3 | |
| SCHEMBL12185408 | 0.94 | MERTK (1.00) | MERTKAXLTYRO3 | |
| SCHEMBL2599113 | 0.91 | MERTK (0.83) | MERTKAXLTYRO3 | |
| SCHEMBL12185748 | 0.90 | MERTK (1.00) | MERTKAXLTYRO3 | |
| SCHEMBL12185202 | 0.90 | MERTK (1.00) | MERTKAXLTYRO3 | |
| SCHEMBL12185200 | 0.90 | MERTK (1.00) | MERTKAXLTYRO3 | |
| SCHEMBL12185235 | 0.90 | MERTK (0.85) | MERTKAXLTYRO3 | |
| SCHEMBL12185760 | 0.90 | MERTK (1.00) | MERTKAXLTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9744172-B2 | Pyrazolopyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744172-B2 | Pyrazolopyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-08-29 | — | — | US | disclosed |
| US-9744172-B2 | Pyrazolopyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-08-29 | — | — | US | disclosed |
| US-9555030-B2 | Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-31 | — | — | US | disclosed |
| US-9555030-B2 | Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-31 | — | — | US | disclosed |
| US-9555030-B2 | Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160279132-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-29 | — | — | US | disclosed |
| US-20160279132-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-09-29 | — | — | US | disclosed |
| US-9290499-B2 | Pyrazolopyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-03-22 | — | — | US | disclosed |
| US-9290499-B2 | Pyrazolopyrimidine compounds for the treatment of cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2016-03-22 | — | — | US | disclosed |
| US-20150290212-A1 | THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| US-20150290212-A1 | THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| EP-2571361-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | The University of North Carolina At Chapel Hill (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20130059836-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-03-07 | — | — | US | disclosed |
| US-20130059836-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2013-03-07 | — | — | US | disclosed |
| WO-2011146313-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011146313-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279132-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | DPYD, TP53, TYMP | MERTK 2088/4885AXL 1864/4885TYRO3 1899/4885 |
| US-20150290212-A1 | THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY | MERTK, TK1, FLT3 | MERTK 1/4885AXL 20/4885TYRO3 32/4885 |
| US-20130059836-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS FOR THE TREATMENT OF CANCER | DPYD, TYMP, TP53 | MERTK 2120/4885AXL 1815/4885TYRO3 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.